Anti-Idiotype Antibodies as Potential Therapeutic Agents for Human Breast Cancer

Bhattacharya‐Chatterjee, Malaya; Mrozek, E; Mukerjee, Sonjoy; Ceriani, Roberto L.; Köhler, Heinz; Foon, Kenneth A.

doi:10.1007/978-1-4615-2443-4_13

Cited by 10 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TriAb is the aluminum hydroxide precipate of 11D10, a murine monoclonal anti-idiotype antibody that mimics an epitope of the human milk fat globule (HMFG) protein. [29][30][31][32] HMFG is a tumor-associated antigen expressed on the surface of over 90% of human breast cancers; this antigen shares a similar amino acid sequence with MUC-1 mucin. HMFG is not expressed in normal breast tissue, but is also found on lung, ovarian, endometrial, and pancreatic cancer cells.…”

mentioning

confidence: 99%

“…11D10 has only minimal reactivity with normal tissues, namely the alveolar lining of the lungs and the brush border of the renal tubules. 32,33 HMFG itself is a poor immunogen, and purified antigen is not available for human vaccination. 32,33 However, a murine monoclonal antibody, MC-10, was developed that identifies the epitope of HMFG.…”

mentioning

confidence: 99%

“…32,33 HMFG itself is a poor immunogen, and purified antigen is not available for human vaccination. 32,33 However, a murine monoclonal antibody, MC-10, was developed that identifies the epitope of HMFG. MC-10 was then used as an immunizing antibody (Ab1) in mice to produce 11D10 (Ab2).…”

mentioning

confidence: 99%

“…MC-10 was then used as an immunizing antibody (Ab1) in mice to produce 11D10 (Ab2). 32,33 11D10, or Triab, can thus serve as a surrogate for the HMFG antigen for clinical vaccination. Initial studies in breast cancer patients not undergoing ASCT demonstrated that intracutaneous TriAb can result in the generation of Ab3 antibody responses that bind to purified HMFG and react by immunoperoxidase staining to HMFG-positive tumor specimens.…”

mentioning

confidence: 99%

“…As well, immunization with TriAb has been shown to elicit idiotype-specific T cell proliferative responses as well as responses to the HMFG antigen. [32][33][34] In this pilot study, TriAb was utilized after recovery from ASCT to try to induce anti-tumor immunity of potential therapeutic benefit.…”

mentioning

confidence: 99%

See 4 more Smart Citations

Use of the anti-idiotype antibody vaccine TriAb after autologous stem cell transplantation in patients with metastatic breast cancer

Reece

Foon

Bhattacharya‐Chatterjee

et al. 2000

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Between April 1997 and March 1998 we evaluated the immune response and outcome in 11 chemosensitive patients who were treated with the anti-idiotype antibody vaccine TriAb after recovery from intensive therapy and autologous stem cell transplant (ASCT). Triab was commenced after recovery from the acute effects of ASCT; a minimum interval of 1 month was required from completion of consolidation radiotherapy, if given. Although intensive therapy and autologous stem cell transplantation (ASCT) produces durable progression-free survival in a small proportion of women with metastatic breast cancer, the majority of patients relapse despite the procedure. 1 A number of different intensive chemotherapeutic agents and dose schedules have been evaluated, but none has clearly produced superior results. 1,2 One approach to try to improve the outcome involves the use of immunotherapy in conjunction with ASCT. The use of immunebased therapy has particular appeal after ASCT, at which time the tumor burden may be small. Several strategies have been proposed in breast cancer patients undergoing ASCT, including the use of cyclosporine to evoke an auto-

show abstract

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations